
Antharis Secures Lonza ADC Tech to Target Gastrointestinal Cancers
Antharis Therapeutics has signed an exclusive licensing deal with Lonza to deploy site-specific, dual-payload antibody-drug conjugate technologies. The partnership aims to accelerate the development of next-generation therapies for gastrointestinal cancers, focusing on overcoming multi-drug resistance and improving survival rates in patients with significant unmet medical needs.



























